好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Association Between DMD Genotype and Neurodevelopmental Concerns in Childhood-Onset Dystrophinopathy Using Population-Based Surveillance Data
Child Neurology and Developmental Neurology
P7 - Poster Session 7 (5:00 PM-6:00 PM)
6-005

We investigated the association of DMD genotype and neurodevelopmental concerns using population-based surveillance data to improve the generalizability of knowledge and better inform clinical care and public health policy.

Extant studies have shown that individuals with dystrophinopathies with distal DMD variants have higher frequencies of co-occurring neurodevelopmental concerns, compared to those with proximal DMD variants. Whether the reported co-occurrences between DMD genotype and neurodevelopmental concerns are generalizable is not known.

We used the population-based Muscular Dystrophy Surveillance, Tracking and Research Network (MD STARnet) data (n = 350) and analyzed neurodevelopmental concerns as a function of DMD genotype, and calculated the frequencies of speech/language delay (SLD), autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), cognitive dysfunction, intellectual disability (ID), and global developmental delay (GDD). We defined proximal DMD variants as those located 5’ to DMD exon 45, and distal DMD variants as those located 3’ of and including DMD exon 45. Distal DMD variants were sub-classified into those with very distal variants in DMD exons 63-79.

SLD were the most common neurodevelopmental concern in our dystrophinopathies cohort (50%). The frequencies of ASD, ADHD, OCD, GDD were comparable between those individuals with proximal versus distal DMD variants. Although multiple neurodevelopmental concerns were more frequent in individuals with distal DMD variants (47%) compared to those individuals with proximal DMD variants (41%), the difference did not reach statistical significance. Individuals with variants in DMD exons 63 to 79 had highest frequencies of ID (43%) and GDD (86%), as well as multiple neurodevelopmental concerns (86%).

There was no statistically significant association between the burden of neurodevelopmental concerns and DMD genotype in the MDSTARnet data but dystrophinopathy individuals with variants located in DMD exons 63 to 79 had statistically significant higher frequencies of ID, GDD, and multiple neurodevelopmental concerns.

Authors/Disclosures
Andrea He
PRESENTER
The institution of Miss He has received research support from AAN.
Tahereh Neyaz Ms. Neyaz has nothing to disclose.
Vinay Bhandaru, MS Mr. Bhandaru has nothing to disclose.
Madeline Rice, PhD The institution of Dr. Rice has received research support from NIH.
Natalie Street, MD No disclosure on file
Katherine D. Mathews, MD, FAAN (University of Iowa - Dept of Pediatrics) Dr. Mathews has received personal compensation for serving as an employee of Avidity Bioscience. The institution of Dr. Mathews has received research support from NIH. The institution of Dr. Mathews has received research support from Centers for Disease Control and Prevention. The institution of Dr. Mathews has received research support from Muscular Dystrophy Association . The institution of Dr. Mathews has received research support from Friedreich's Ataxia Research Alliance . The institution of Dr. Mathews has received research support from Sarepta . The institution of Dr. Mathews has received research support from Pfizer. The institution of Dr. Mathews has received research support from Reata . The institution of Dr. Mathews has received research support from PTC Therapeutics, Inc. The institution of Dr. Mathews has received research support from Italfarmaco . The institution of Dr. Mathews has received research support from AMO. The institution of Dr. Mathews has received research support from FibroGen. The institution of Dr. Mathews has received research support from Capricor. The institution of Dr. Mathews has received research support from edgewise. The institution of Dr. Mathews has received research support from biogen.
Yedatore S. Venkatesh, MD, FAAN (University of SC School of Medicine) Dr. Venkatesh has nothing to disclose.
Emma Ciafaloni, MD, FAAN (University of Rochester Medical Center) Dr. Ciafaloni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx, Alexion, Sarepta, UCB, Hoffman-LaRoche, Biogen. Dr. Ciafaloni has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis, AnnJi Pharmaceutical, ML-BIO, Avidity. The institution of Dr. Ciafaloni has received research support from CDC, CureSMA, FDA, Orphazyme, Sarepta, PCORI, Neurogene. Dr. Ciafaloni has received publishing royalties from a publication relating to health care.
James F. Howard, Jr., MD, FAAN (The University of North Carolina, Dept of Neurology, CB 7025) Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx . Dr. Howard has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron Pharmaceuticals. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals. Dr. Howard has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AMGEN (Horizon Therapeutics). Dr. Howard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Howard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven Ltd. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CorEvitas. Dr. Howard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck EMD Serono. Dr. Howard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cartesian Therapeutics. Dr. Howard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NMD Pharma. Dr. Howard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for H. Lundbeck A/S. Dr. Howard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Seismic Therapeutics. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Howard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vor Biopharma. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Academic CME. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for PeerView CME. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Platform Q CME. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for MJH LifeSci. Dr. Howard has or had stock in Johnson & Johnson dividends.Dr. Howard has or had stock in Pfizer dividends. An immediate family member of Dr. Howard has or had stock in GlaxoSmithKline dividends.Dr. Howard has or had stock in Bristol Myer Squbb dividends.Dr. Howard has or had stock in AbbieVie Inc. The institution of Dr. Howard has received research support from Alexion Pharmaceuticals. The institution of Dr. Howard has received research support from argenx . The institution of Dr. Howard has received research support from UCB Biosciences. The institution of Dr. Howard has received research support from NIH. The institution of Dr. Howard has received research support from Centers for Disease Control/Research Triangle Institute. The institution of Dr. Howard has received research support from Cartestian Therapeutics. The institution of Dr. Howard has received research support from NMD Pharma. The institution of Dr. Howard has received research support from Ad Scientiam. The institution of Dr. Howard has received research support from Merck EMD Serono. Dr. Howard has a non-compensated relationship as a Scientific Advisiory Board member, Committee member with Myasthenia Gravis Foundation of America that is relevant to AAN interests or activities. Dr. Howard has a non-compensated relationship as a Committee member with American Assoc Neuromuscular and Electrodiagnostic Medicine that is relevant to AAN interests or activities.
Kristin M. Conway, PhD Dr. Conway has nothing to disclose.
Mathula Thangarajh, MD, PhD, FAAN Dr. Thangarajh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta. Dr. Thangarajh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for NS Pharma.